Inventiva (IVA) Non-Current Assets (2018 - 2025)
Inventiva (IVA) posted quarterly Non-Current Assets of $5.9 million for Q4 2025, down 99.93% year-over-year from $8.0 billion in Q4 2024, and down 65.6% quarter-over-quarter from $17.1 million in Q2 2025.
Inventiva (IVA) Non-Current Assets (2018 - 2025) Analysis & Trends
Inventiva's Non-Current Assets history runs 8 years deep, the most recent figure standing at $5.9 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 99.93% year-over-year to $5.9 million; the TTM figure through Dec 2025 stood at $67.5 million (down 99.15% YoY), while the FY2025 annual figure was $5.9 million, down 99.93% from the prior year.
- Non-Current Assets for Q4 2025 stood at $5.9 million, down from $17.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $9.0 billion in Q2 2022, with the low at $5.9 million in Q4 2025.
- The 5-year median for Non-Current Assets is $18.5 million (2024), against an average of $2.2 billion.
- The sharpest annual moves came in 2021 and 2025: Non-Current Assets surged 103703.96% in 2021, then slumped 99.93% in 2025.
- Inventiva's Non-Current Assets stood at $7.3 billion in 2021, then sank by 99.87% to $9.8 million in 2022, then surged by 134.27% to $23.0 million in 2023, then surged by 34548.63% to $8.0 billion in 2024, then plunged by 99.93% to $5.9 million in 2025.
- Business Quant data shows IVA's Non-Current Assets at $5.9 million in Q4 2025, $17.1 million in Q2 2025, and $8.0 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | 5.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.87 Mn |
| Jun 30, 2025 | 17.06 Mn |
| Dec 31, 2024 | 7.97 Bn |
| Jun 30, 2024 | 18.54 Mn |
| Dec 31, 2023 | 22.99 Mn |
| Jun 30, 2023 | 20.09 Mn |
| Dec 31, 2022 | 9.82 Mn |
| Jun 30, 2022 | 9.03 Bn |
| Dec 31, 2021 | 7.33 Bn |
| Jun 30, 2021 | 8.89 Mn |
| Mar 31, 2021 | 8.21 Mn |
| Dec 31, 2020 | 7.06 Mn |
| Jun 30, 2020 | 9.42 Mn |
| Dec 31, 2019 | 8.95 Mn |
| Dec 31, 2018 | 9.33 Mn |